HomeNew JAK Inhibitors

New JAK Inhibitors

Catalog No. Product Name Information
S3521 Golidocitinib(AZD4205) Golidocitinib (AZD4205) (Compound 21) is a highly selective and potent inhibitor of Janus kinase 1 (JAK1), with an IC50 of 0.07 μM for JAK1 and much weaker inhibition of JAK2 (IC50 > 15 μM). It also exhibits potent antitumor effects in NSCLC xenograft models in preclinical studies.
F2644 Phospho-JAK1 (Tyr1034/1035)/JAK2 (Tyr1007/1008) Antibody [L3G19]
E5866 Cenacitinib Cenacitinib is an orally potent and selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). It exhibits significant efficacy and can be used in research for the treatment of moderate to severe psoriasis.
E4720 Flonoltinib Flonoltinib (JAK2/FLT3-IN-1) is a potent and selective dual inhibitor of JAK2 and FLT3, with IC50 of of 0.8, 1.4, and 15 nM against JAK2, JAK2V617F, and FLT3, respectively, in in vitro kinase assays. It also inhibits cell proliferation and induces G2/M cell cycle arrest and apoptosis in Hemophagocytic Lymphohistiocytosis (HLH) patients' CD8+T cells, CTLL2 cells, and RAW 264.7 cells.
E8276 Golidocitinib 1-hydroxy-2-naphthoate Golidocitinib 1-hydroxy-2-naphthoate is a derivative of Golidocitinib, an oral, potent, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 70 nM. It exhibits enhnaced antitumor activity and can be used for the treatment of cancer, including peripheral T cell lymphoma (PTCL).
≡ All JAK Inhibitors